Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates

Financial Performance - Dianthus Therapeutics, Inc. reported a quarterly loss of $0.97 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.86, representing an earnings surprise of -12.79% [1] - The company posted revenues of $0.4 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 39.63%, compared to revenues of $2.17 million in the same quarter last year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.81 on revenues of $0.64 million, and for the current fiscal year, it is -$3.41 on revenues of $2.27 million [7] Stock Performance - Dianthus Therapeutics, Inc. shares have increased by approximately 52.3% since the beginning of the year, outperforming the S&P 500's gain of 15.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Dianthus Therapeutics belongs, is currently in the top 40% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]